Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy

Molecular Nutrition and Food Research

Volumn 53, Issue 1, 2009, Pages 87-103

  Tonissen, Kathryn F ^a   Trapani, Giovanna Di ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Apoptosis; Cancer; Redox control; Thioredoxin

Indexed keywords

ANTINEOPLASTIC AGENT; REACTIVE OXYGEN METABOLITE; SCAVENGER; THIOREDOXIN; THIOREDOXIN REDUCTASE;

APOPTOSIS; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; MITOCHONDRION; NEOPLASM; PATHOLOGY; PHYSIOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; APOPTOSIS; FREE RADICAL SCAVENGERS; HUMANS; MITOCHONDRIA; NEOPLASMS; REACTIVE OXYGEN SPECIES; THIOREDOXIN-DISULFIDE REDUCTASE; THIOREDOXINS;

EID: 58149352993     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.200700492     Document Type: Review

References (136)

1. Orrenius, S., Gogvadze, V., Zhivotovsky, B., Mitochondrial oxidative stress: Implications for cell death, Annu. Rev. Pharmacol. Toxicol. 2007, 47, 143-183.
2. Danial, N. N., Korsmeyer, S. J., Cell death: Critical control points, Cell 2004, 116, 205-219.
3. Shi, Y., Caspase activation, inhibition, and reactivation: A mechanistic view, Protein Sci. 2004, 13, 1979-1987.
4. Green, D. R., Reed, J. C., Mitochondria and apoptosis, Science 1998, 281, 1309-1312.
5. Cory, S., Huang, D. C., Adams, J. M., The Bcl-2 family: Roles in cell survival and oncogenesis, Oncogene 2003, 22, 8590-8607.
6. Kuwana, T., Mackey, M. R., Perkins, G., Ellisman, M. H., et al., Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane, Cell 2002, 111, 331-342.
7. Schwarz, M., Andrade-Navarro, M. A., Gross, A., Mitochondrial carriers and pores: Key regulators of the mitochondrial apoptotic program? Apoptosis 2007, 12, 869-876.
8. Zou, H., Li, Y., Liu, X., Wang, X., An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9, J. Biol. Chem. 1999, 274, 11549-11556.
9. Srinivasula, S. M., Ahmad, M., Fernandes-Alnemri, T., Alnemri, E. S., Autoactivation of procaspase-9 by Apaf-1-mediatedoligomerization, Mol. Cell 1998, 1, 949-957.
10. Deveraux, Q. L., Roy, N., Stennicke, H. R., Van Arsdale, T., et al., IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases, EMBO J. 1998, 77, 2215-2223.
11. Du, C., Fang, M., Li, Y., Li, L., Wang, X., Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition, Cell 2000, 102, 33-42.
12. Kyriakis, J. M., Avruch, J., Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation, Physiol. Rev. 2001, 81, 807-869.
13. Ichijo, H., Nishida, E., Irie, K., ten Dijke, P., et al., Induction of apoptosis by ASK 1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways, Science 1997, 275, 90-94.
14. Cai, B., Chang, S. H., Becker, E. B., Bonni, A., Xia, Z., p38 MAP kinase mediates apoptosis through phosphorylation of BimEL at Ser-65, J. Biol. Chem. 2006, 281, 25215-25222.
15. Lei, K., Davis, R. J., JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis, Proc. Natl. Acad. Sci. USA 2003, 100, 2432-2437.
16. Kim, B. J., Ryu, S. W., Song, B. J., JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells, J. Biol. Chem. 2006, 281, 21256-21265.
17. Buschmann, T., Potapova, O., Bar-Shira, A., Ivanov, V. N., et al., Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress, Mol. Cell. Biol. 2001, 21, 2743-2754.
18. Levine, A. J., p53, the cellular gatekeeper for growth and division, Cell 1997, 88, 323-331.
19. Rossi, D., Gaidano, G., Messengers of cell death: Apoptotic signaling in health and disease, Haematologica 2003, 88, 212-218.
20. Nordberg, J., Arner, E. S., Reactive oxygen species, antioxidants, and the mammalian thioredoxin system, Free Radio. Biol. Med. 2001, 31, 1287-1312.
21. Fleury, C., Mignotte, B., Vayssiere, J. L., Mitochondrial reactive oxygen species in cell death signaling, Biochimie 2002, 84, 131-141.
22. Zhang, D. X., Gutterman, D. D., Mitochondrial reactive oxygen species-mediated signaling in endothelial cells, Am. J. Physiol. Heart Circ. Physiol. 2007, 292, H2023-H2031.
23. Carmody, R. J., McGowan, A. J., Cotter, T. G., Reactive oxygen species as mediators of photoreceptor apoptosis in vitro, Exp. Cell Res. 1999, 248, 520-530.
24. Ott, M., Robertson, J. D., Gogvadze, V., Zhivotovsky, B., Orrenius, S., Cytochrome c release from mitochondria proceeds by a two-step process, Proc. Natl. Acad. Sci. USA 2002, 99, 1259-1263.
25. Kagan, V. E., Tyurin, V. A., Jiang, J., Tyurina, Y. Y., et al., Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors, Nat. Chem. Biol. 2005, 1, 223-232.
26. Holmgren, A., Thioredoxin, Annu. Rev. Biochem. 1985, 54, 237-271.
27. Rhee, S. G., Chae, H. Z., Kim, K., Peroxiredoxins: A historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling, Free Radio. Biol. Med. 2005, 38, 1543-1552.
28. Damdimopoulos, A. E., Miranda-Vizuete, A., Pelto-Huikko, M., Gustafsson, J. A., Spyrou, G., Human mitochondrial thioredoxin. Involvement in mitochondrial membrane potential and cell death, J. Biol. Chem. 2002, 277, 33249-33257.
29. Miranda-Vizuete, A., Damdimopoulos, A. E., Pedrajas, J. R., Gustafsson, J. A., Spyrou, G., Human mitochondrial thioredoxin reductase cDNA cloning, expression and genomic organization, Eur. J. Biochem. 1999, 261, 405-412.
30. Watabe, S., Hiroi, T., Yamamoto, Y., Fujioka, Y., et al., SP-22 is a thioredoxin-dependent peroxide reductase in mitochondria, Eur. J. Biochem. 1997, 249, 52-60.
31. Patenaude, A., Ven Murthy, M. R., Mirault, M. E., Mitochondrial thioredoxin system: Effects of TrxR2 overexpression on redox balance, cell growth, and apoptosis, J. Biol. Chem. 2004, 279, 27302-27314.
32. Haendeler, J., Thioredoxin-1 and posttranslational modifications, Antioxid. Redox Signal. 2006, 8, 1723-1728.
33. Weichsel, A., Gasdaska, J. R., Powis, G., Montfort, W. R., Crystal structures of reduced, oxidized, and mutated human thioredoxins: Evidence for a regulatory homodimer, Structure 1996, 4, 735-751.
34. Zhong, L., Holmgren, A., Essential role of selenium in the catalytic activities of mammalian thioredoxin reductase revealed by characterization of recombinant enzymes with selenocysteine mutations, J. Biol. Chem. 2000, 275, 18121-18128.
35. Zhong, L., Arner, E. S., Holmgren, A., Structure and mechanism of mammalian thioredoxin reductase: The active site is a redox-active selenolthiol/selenenylsulfide formed from the conserved cysteine-selenocysteine sequence, Proc. Natl. Acad. Sci. USA 2000, 97, 5854-5859.
36. Spyrou, G., Enmark, E., Miranda-Vizuete, A., Gustafsson, J., Cloning and expression of a novel mammalian thioredoxin, J. Biol. Chem. 1997, 272, 2936-2941.
37. Sun, Q. A., Wu, Y., Zappacosta, F., Jeang, K. T., et al., Redox regulation of cell signaling by selenocysteine in mammalian thioredoxin reductases, J. Biol. Chem. 1999, 274, 24522-24530.
38. Sun, Q. A., Kirnarsky, L., Sherman, S., Gladyshev, V. N., Selenoprotein oxidoreductase with specificity for thioredoxin and glutathione systems, Proc. Natl. Acad. Sci. USA 2001, 95, 3673-3678.
39. Laurent, T. C., Moore, E. C., Reichard, P., Enzymatic synthesis of deoxyribonucleotides. VI. Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli B. J. Biol. Chem. 1964, 239, 3436-3444.
40. Arner, E. S., Holmgren, A., Physiological functions of thioredoxin and thioredoxin reductase, Eur. J. Biochem. 2000, 267, 6102-6109.
41. Nakamura, H., Nakamura, K., Yodoi, J., Redox regulation of cellular activation, Annu. Rev. Immunol. 1997, 15, 351-369.
42. Powis, G., Montfort, W. R., Properties and biological activities of thioredoxins, Annu. Rev. Pharmacol. Toxicol 2001, 41, 261-295.
43. Angelini, G., Gardella, S., Ardy, M., Ciriolo, M. R., et al., Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation, Proc. Natl. Acad. Sci. USA 2002, 99, 1491-1496.
44. Bjornstedt, M., Xue, J., Huang, W., Akesson, B., Holmgren, A., The thioredoxin and glutaredoxin systems are efficient electron donors to human plasma glutathione peroxidase, J. Biol. Chem. 1994, 269, 29382-29384.
45. Stadtman, E. R., Moskovitz, J., Berlett, B. S., Levine, R. L., Cyclic oxidation and reduction of protein methionine residues is an important antioxidant mechanism, Mol. Cell. Biochem. 2002, 234-235, 3-9.
46. Das, K. C., Das, C. K., Thioredoxin, a singlet oxygen quencher and hydroxyl radical scavenger: Redox independent functions, Biochem. Biophys. Res. Commun. 2000, 277, 443-447.
47. Holmgren, A., Bovine thioredoxin system. Purification of thioredoxin reductase from calf liver and thymus and studies of its function in disulfide reduction, J. Biol. Chem. 1977, 252, 4600-4606.
48. Arner, E. S., Nordberg, J., Holmgren, A., Efficient reduction of lipoamide and lipoic acid by mammalian thioredoxin reductase, Biochem. Biophys. Res. Commun. 1996, 225, 268-274.
49. Luthman, M., Holmgren, A., Rat liver thioredoxin and thioredoxin reductase: Purification and characterization, Biochemistry 1982, 21, 6628-6633.
50. Cenas, N., Nivinskas, H., Anusevicius, Z., Sarlauskas, J., et al., Interactions of quinones with thioredoxin reductase: A challenge to the antioxidant role of the mammalian seleno-protein, J. Biol. Chem. 2004, 279, 2583-2592.
51. Bjornstedt, M., Kumar, S., Holmgren, A., Selenodiglutathione is a highly efficient oxidant of reduced thioredoxin and a substrate for mammalian thioredoxin reductase, J. Biol. Chem. 1992, 267, 8030-8034.
52. Kumar, S., Bjornstedt, M., Holmgren, A., Selenite is a substrate for calf thymus thioredoxin reductase and thioredoxin and elicits a large nonstoichiometric oxidation of NADPH in the presence of oxygen, Eur. J. Biochem. 1992, 207, 435-439.
53. Saitoh, M., Nishitoh, H., Fujii, M., Takeda, K., et al., Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1, EMBO J. 1998, 17, 2596-2606.
54. Fujino, G., Noguchi, T., Matsuzawa, A., Yamauchi, S., et al., Thioredoxin and TRAF family proteins regulate ROS-dependent activation of ASK1 through reciprocal modulation of the N-terminal homophilic interaction of ASK1, Mol. Cell. Biol. 2007, 27, 8152-8163.
55. Liu, Y., Min, W., Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner, Circ. Res. 2002, 90, 1259-1266.
56. Zhang, R., Al-Lamki, R., Bai, L., Streb, J. W., et al., Thiore-doxin-2 inhibits mitochondria-located ASK1-mediated apoptosis in a JNK-independent manner, Circ. Res. 2004, 94, 1483-1491.
57. Mitchell, D. A., Morton, S. U., Fernhoff, N. B., Marietta, M. A., Thioredoxin is required for S-nitrosation of procaspase-3 and the inhibition of apoptosis in Jurkat cells, Proc. Natl. Acad. Sci. USA 2007, 104, 11609-11614.
58. Kim, J. E., Tannenbaum, S. R., S-Nitrosation regulates the activation of endogenous procaspase-9 in HT-29 human colon carcinoma cells, J. Biol. Chem. 2004, 279, 9758-9764.
59. Matthews, J., Wakasugi, N., Virelizier, J., Yodoi, J., Hay, R., Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62, Nucl. Acids Res. 1992, 20, 3821-3830.
60. Shishodia, S., Aggarwal, B. B., Nuclear factor-kappa B activation: A question of life or death, J. Biochem. Mol. Biol. 2002, 35, 28-40.
61. Wang, C. Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., Baldwin, A. S., Jr., NF-kappa B antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and C-IAP2 to suppress caspase-8 activation, Science 1998, 281, 1680-1683.
62. Ueno, M., Masutani, H., Arai, R. J., Yamauchi, A., et al., Thioredoxin-dependent redox regulation of p53-mediated p21 activation, J. Biol. Chem. 1999, 274, 35809-35815.
63. Arner, E. S., Holmgren, A., The thioredoxin system in cancer, Semin. Cancer Biol. 2006, 16, 420-426.
64. Roos, W. P., Kaina, B., DNA damage-induced cell death by apoptosis, Trends Mol. Med. 2006, 12, 440-450.
65. Nishiyama, A., Matsui, M., Iwata, S., Hirota, K., et al., Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression, J. Biol. Chem. 1999, 274, 21645-21650.
66. Rigobello, M. P., Scutari, G., Folda, A., Bindoli, A., Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c, Biochem. Pharmacol. 2004, 67, 689-696.
67. Chen, Y., Cai, J., Jones, D. P., Mitochondrial thioredoxin in regulation of oxidant-induced cell death, FEBS Lett. 2006, 580, 6596-6602.
68. Berggren, M., Gallegos, A., Gasdaska, J., Gasdaska, P., et al., Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia, Anticancer Res. 1996, 16, 3459-3466.
69. Lincoln, D. T., Eli Emadi, E. M., Tonissen, K. F., Clarke, F. M., The thioredoxin-thioredoxin reductase system: Over-expression in human cancer, Anticancer Res. 2003, 23, 2425-2434.
70. Shao, L., Diccianni, M. B., Tanaka, T., Gribi, R., et al., Thioredoxin expression in primary T-cell acute lymphoblastic leukemia and its therapeutic implication, Cancer Res. 2001, 61, 7333-7338.
71. Soderberg, A., Sahaf, B., Rosen, A., Thioredoxin reductase, a redox-active selenoprotein, is secreted by normal and neoplastic cells: Presence in human plasma, Cancer Res. 2000, 60, 2281-2289.
72. Powis, G., Oblong, J. E., Gasdaska, P. Y., Berggren, M., et al., The thioredoxin/thioredoxin reductase redox system and control of cell growth, Oncol. Res. 1994, 6, 539-544.
73. Wakasugi, N., Tagaya, Y., Wakasugi, H., Mitsui, A., et al., Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I-and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2, Proc. Natl. Acad. Sci. USA 1990, 87, 8282-8286.
74. Welsh, S., Bellamy, W., Briehl, M., Powis, G., The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis, Cancer Res. 2002, 62, 5089-5095.
75. Farina, A. R., Tacconelli, A., Cappabianca, L., Masciulli, M. P., et al., Thioredoxin alters the matrix metalloproteinase/tissue inhibitors of metalloproteinase balance and stimulates human SK-N-SH neuroblastoma cell invasion, Eur. J. Biochem. 2001, 268, 405-413.
76. Yamada, M., Tomida, A., Yoshikawa, H., Taketani, Y., Tsuruo, T., Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines, Clin. Cancer Res. 1996, 2, 427-432.
77. Kim, S. J., Miyoshi, Y., Taguchi, T., Tamaki, Y., et al., High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer, Clin. Cancer Res. 2005, 11, 8425-8430.
78. Iwao-Koizumi, K., Matoba, R., Ueno, N., Kim, S. J., et al., Prediction of docetaxel response in human breast cancer by gene expression profiling, J. Clin. Oncol. 2005, 23, 422-431.
79. Powis, G., Kirkpatrick, D. L., Thioredoxin signaling as a target for cancer therapy, Curr. Opin. Pharmacol. 2007, 7, 392-397.
80. Kunkel, M. W., Kirkpatrick, D. L., Johnson, J. I., Powis, G., Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs, Anticancer Drug Design 1997, 12, 659-670.
81. Kirkpatrick, D. L., Ehrmantraut, G., Stettner, S., Kunkel, M., Powis, G., Redox active disulfides: The thioredoxin system as a drug target, Oncol. Res. 1997, 9, 351-356.
82. Kirkpatrick, D. L., Kuperus, M., Dowdeswell, M., Potier, N., et al., Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides, Biochem. Pharmacol. 1998, 55, 987-994.
83. Baker, A. F., Dragovich, T., Tate, W. R., Ramanathan, R. K., et al., The antitumor thioredoxin-1 inhibitor PX-12 (1-meth-ylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma, J. Lab. Clin. Med. 2006, 147, 83-90.
84. Welsh, S. J., Williams, R. R., Birmingham, A., Newman, D. J., et al., The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1 alpha and vascular endothelial growth factor formation, Mol. Cancer Ther. 2003, 2, 235-243.
85. Ramanathan, R. K., Kirkpatrick, D. L., Belani, C. P., Fried-land, D., et al., A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors, Clin. Cancer Res. 2007, 13, 2109-2114.
86. Thiagalingam, S., Cheng, K. H., Lee, H. J., Mineva, N., et al., Histone deacetylases: Unique players in shaping the epigenetic histone code, Ann. N. Y. Acad. Sci. 2003, 983, 84-100.
87. Marks, P. A., Thioredoxin in cancer - Role of histone deacetylase inhibitors, Semin. Cancer Biol. 2006, 16, 436-443.
88. Zhang, C., Richon, V., Ni, X., Talpur, R., Duvic, M., Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action, J. Invest. Dermatol. 2005, 125, 1045-1052.
89. Ungerstedt, J. S., Sowa, Y., Xu, W. S., Shao, Y., et al., Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors, Proc. Natl. Acad. Sci. USA 2005, 102, 673-678.
90. Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., Pazdur, R., FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma, Oncologist 2007, 12, 1247-1252.
91. Glaser, K. B., HDAC inhibitors: Clinical update and mechanism-based potential, Biochem. Pharmacol. 2007, 74, 659-671.
92. Butler, L., Zhou, X., Xu, W., Scher, H., et al., The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin, Proc. Natl. Acad. Sci. USA 2002, 99, 11700-11705.
93. Xu, W., Ngo, L., Perez, G., Dokmanovic, M., Marks, P. A., Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor, Proc. Natl. Acad. Sci. USA 2006, 103, 15540-15545.
94. Tan, J., Zhuang, L., Jiang, X., Yang, K. K., et al., Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity, J. Biol. Chem. 2006, 281, 10508-10515.
95. Boulikas, T., Vougiouka, M., Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs, Oncol. Rep. 2004, 11, 559-595.
96. Urig, S., Becker, K., On the potential of thioredoxin reductase inhibitors for cancer therapy, Semin. Cancer Biol. 2006, 16, 452-465.
97. Wang, D., Lippard, S. J., Cellular processing of platinum anticancer drugs, Nat. Rev. Drug Discov. 2005, 4, 307-320.
98. Amer, E. S., Nakamura, H., Sasada, T., Yodoi, J., et al., Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex, Free Radic. Biol. Med. 2001, 31, 1170-1178.
99. Sasada, T., Nakamura, H., Ueda, S., Sato, N., et al., Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II), Free Radic. Biol. Med. 1999, 27, 504-514.
100. Witte, A. B., Anestal, K., Jerremalm, E., Ehrsson, H., Arner, E. S., Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds, Free Radic. Biol. Med. 2005, 39, 696-703.
101. Zhong, L., Arn-er, E. S., Ljung, J., Aslund, F., Holmgren, A., Rat and calf thioredoxin reductase are homologous to glutathione reductase with a carboxyl-terminal elongation containing a conserved catalytically active penultimate seleno-cysteine residue, J. Biol. Chem. 1998, 273, 8581-8591.
102. Anestal, K., Amer, E. S., Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine, J. Biol. Chem. 2003, 278, 15966-15972.
103. Kaludjerovic, G. N., Miljkovic, D., Momcilovic, M., Djinovic, V. M. et al., Novel platinum(IV) complexes induce rapid tumor cell death in vitro, Int. J. Cancer 2005, 116, 479-486.
104. Milacic, V., Fregona, D., Dou, Q. P., Gold complexes as prospective metal-based anticancer drugs, Histol. Histopathol. 2008, 23, 101-108.
105. Ronconi, L., Giovagnini, L., Marzano, C., Bettio, F., et al., Gold dithiocarbamate derivatives as potential antineoplastic agents: Design, spectroscopic properties, and in vitro antitumor activity, Inorg. Chem. 2005, 44, 1867-1881.
106. Ronconi, L., Marzano, C., Zanello, P., Corsini, M., et al., Gold(III) dithiocarbamate derivatives for the treatment of cancer: Solution chemistry, DNA binding, and hemolytic properties, J. Med. Chem.2006, 49, 1648-1657.
107. Gromer, S., Arscott, L. D., Williams, C. H., Jr., Schirmer, R. H., Becker, K., Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds, J. Biol. Chem. 1998, 273, 20096-20101.
108. Marzano, C., Gandin, V., Folda, A., Scutari, G., et al., Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells, Free Radic. Biol. Med. 2007, 42, 872-881.
109. Omata, Y., Folan, M., Shaw, M., Messer, R. L., et al, Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1), Toxicol. In Vitro 2006, 20, 882-890.
110. Rackham, O., Nichols, S. J., Leedman, P. J., Berners-Price, S. J., Filipovska, A., A gold(I) phosphine complex selectively induces apoptosis in breast cancer cells: Implications for anticancer therapeutics targeted to mitochondria, Biochem. Pharmacol. 2007, 74, 992-1002.
111. Rigobello, M.P., Messori, L., Marcon, G., Agostina Cinellu, M. et al., Gold complexes inhibit mitochondrial thioredoxin reductase: Consequences on mitochondrial functions, J. Inorg. Biochem. 2004, 98, 1634-1641.
112. Rigobello, M. P., Scutari, G., Boscolo, R., Bindoli, A., Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative, Br. J. Pharmacol. 2002, 136, 1162-1168.
113. Rigobello, M. P., Folda, A., Baldoin, M. C., Scutari, G., Bindoli, A., Effect of auranofin on the mitochondrial generation of hydrogen peroxide. Role of thioredoxin reductase, Free Radic. Res. 2005, 39, 687-695.
114. Venardos, K., Harrison, G., Headrick, J., Perkins, A., Auranofin increases apoptosis and ischaemia-reperfusion injury in the rat isolated heart, Clin. Exp. Pharmacol. Physiol. 2004, 31, 289-294.
115. Coronnello, M., Mini, E., Caciagli, B., Cinellu, M. A., et al., Mechanisms of cytotoxicity of selected organogold(III) compounds, J. Med. Chem. 2005, 48, 6761-6765.
116. Messori, L., Orioli, P., Tempi, C., Marcon, G., Interactions of selected gold(III) complexes with calf thymus DNA, Biochem. Biophys. Res. Commun. 2001, 281, 352-360.
117. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins, Blood 1996, 88, 1052-1061.
118. Douer, D., Tallman, M. S., Arsenic trioxide: New clinical experience with an old medication in hematologic malignancies, J. Clin. Oncol. 2005, 23, 2396-2410.
119. Miller, W. H., Jr., Molecular targets of arsenic trioxide in malignant cells, Oncologist 2002, 7, 14-19.
120. Miller, W. H., Jr., Schipper, H. M., Lee, J. S., Singer, J., Waxman, S., Mechanisms of action of arsenic trioxide, Cancer Res. 2002, 62, 3893-3903.
121. Ralph, S. J., Arsenic-based antineoplastic drugs and their mechanisms of action, Met Based Drugs 2008, 2008, 260146.
122. Lu, J., Chew, E. H., Holmgren, A., Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide, Proc. Natl. Acad. Sci. USA 2007, 104, 12288-12293.
123. Akao, Y., Yamada, H., Nakagawa, Y., Arsenic-induced apoptosis in malignant cells in vitro, Leuk. Lymphoma 2000, 37, 53-63.
124. Yeh, J. Y., Cheng, L. C., Ou, B. R., Whanger, D. P., Chang, L. W., Differential influences of various arsenic compounds on glutathione redox status and antioxidative enzymes in porcine endothelial cells, Cell. Mol. Life Sci. 2002, 59, 1972-1982.
125. Chouchane, S., Snow, E. T., In vitro effect of arsenical compounds on glutathione-related enzymes, Chem. Res. Toxicol. 2001, 14, 517-522.
126. Magda, D., Miller, R. A., Motexafin gadolinium: A novel redox active drug for cancer therapy, Semin. Cancer Biol. 2006, 16, 466-476.
127. Magda, D., Lepp, C., Gerasimchuk, N., Lee, I. et at, Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species, Int. J. Radiat. Oncol. Biol Phys. 2001, 51, 1025-1036.
128. Evens, A. M., Motexafin gadolinium: A redox-active tumor selective agent for the treatment of cancer, Curr. Opin. Oncol. 2004, 16, 576-580.
129. Hashemy, S. I., Ungerstedt, J. S., Zahedi Avval, F., Holmgren, A., Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase, J. Biol. Chem. 2006, 281, 10691-10697.
130. Magda, D., Lecane, P., Miller, R. A., Lepp, C., et al., Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines, Cancer Res. 2005, 65, 3837-3845.
131. Rigobello, M. P., Callegaro, M. T., Barzon, E., Benetti, M., Bindoli, A., Purification of mitochondrial thioredoxin reductase and its involvement in the redox regulation of membrane permeability, Free Radic. Biol. Med. 1998, 24, 370-376.
132. Richards, G. M., Mehta, M. P., Motexafin gadolinium in the treatment of brain metastases, Expert Opin. Pharmacother. 2007, 8, 351-359.
133. Nordberg, J., Zhong, L., Holmgren, A., Arner, E. S., Mammalian thioredoxin reductase is irreversibly inhibited by dinitrohalobenzenes by alkylation of both the redox active selenocysteine and its neighboring cysteine residue, J. Biol. Chem. 1998, 273, 10835-10842.
134. Fang, J., Lu, J., Holmgren, A., Thioredoxin reductase is irreversibly modified by curcumin: A novel molecular mechanism for its anticancer activity, J. Biol. Chem. 2005, 280, 25284-25290.
135. Lu, J., Papp, L. V., Fang, J., Rodriguez-Nieto, S., et al., Inhibition of Mammalian thioredoxin reductase by some flavonoids: Implications for myricetin and quercetin anticancer activity, Cancer Res. 2006, 66, 4410-4418.
136. Terheyden, P., Kortum, A. K., Schulze, H. J., Durani, B., et al., Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: Results of a nationwide survey of the German Dermatologic Co-operative Oncology Group, J. Cancer Res. Clin. Oncol. 2007, 133, 437-444.